DZ3308A1 - 5-alkylpyrido [2,3-d] pyrimidines tyrosine kinase inhibitors - Google Patents

5-alkylpyrido [2,3-d] pyrimidines tyrosine kinase inhibitors

Info

Publication number
DZ3308A1
DZ3308A1 DZ013308A DZ013308A DZ3308A1 DZ 3308 A1 DZ3308 A1 DZ 3308A1 DZ 013308 A DZ013308 A DZ 013308A DZ 013308 A DZ013308 A DZ 013308A DZ 3308 A1 DZ3308 A1 DZ 3308A1
Authority
DZ
Algeria
Prior art keywords
alkylpyrido
pyrimidines
tyrosine kinase
kinase inhibitors
inhibitors
Prior art date
Application number
DZ013308A
Other languages
German (de)
French (fr)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DZ3308A1 publication Critical patent/DZ3308A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DZ013308A 2000-03-06 2001-01-29 5-alkylpyrido [2,3-d] pyrimidines tyrosine kinase inhibitors DZ3308A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
PCT/US2001/002657 WO2001070741A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
DZ3308A1 true DZ3308A1 (en) 2001-09-27

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013308A DZ3308A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido [2,3-d] pyrimidines tyrosine kinase inhibitors

Country Status (36)

Country Link
EP (1) EP1268476A1 (en)
JP (1) JP2003528101A (en)
KR (1) KR20020075805A (en)
CN (1) CN1422268A (en)
AP (1) AP2002002643A0 (en)
AR (1) AR034119A1 (en)
AU (1) AU2001233028A1 (en)
BG (1) BG107161A (en)
BR (1) BR0109056A (en)
CA (1) CA2401368A1 (en)
CO (1) CO5280200A1 (en)
CR (1) CR6736A (en)
CZ (1) CZ20022929A3 (en)
DZ (1) DZ3308A1 (en)
EA (1) EA200200802A1 (en)
EE (1) EE200200506A (en)
GT (1) GT200100037A (en)
HN (1) HN2001000040A (en)
HR (1) HRP20020798A2 (en)
HU (1) HUP0300136A2 (en)
IL (1) IL151480A0 (en)
IS (1) IS6524A (en)
MA (1) MA26881A1 (en)
MX (1) MXPA02008535A (en)
NO (1) NO20024235L (en)
NZ (1) NZ520962A (en)
OA (1) OA12227A (en)
PA (1) PA8513201A1 (en)
PE (1) PE20011177A1 (en)
PL (1) PL358271A1 (en)
SK (1) SK12472002A3 (en)
SV (1) SV2001000338A (en)
TN (1) TNSN01036A1 (en)
WO (1) WO2001070741A1 (en)
YU (1) YU66502A (en)
ZA (1) ZA200207110B (en)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
JP4524072B2 (en) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New compounds
HRP20030624B1 (en) * 2001-02-12 2007-03-31 F. Hoffmann - La Roche Ag 6-substituted pyrido-pyrimidines
KR100540623B1 (en) * 2001-02-26 2006-01-11 다나베 세이야꾸 가부시키가이샤 Pyridopyrimidine or Naphthyridine Derivatives
US20030105115A1 (en) * 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
WO2003000270A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidones and uses thereof
WO2003062236A1 (en) * 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
US7629350B2 (en) 2002-04-19 2009-12-08 Smithkline Beecham Corporation Compounds
WO2004011456A1 (en) 2002-07-31 2004-02-05 Danter Wayne R Protein tyrosine kinase inhibitors
DE60318089T2 (en) 2002-10-09 2008-12-04 Critical Outcome Technologies, Inc. PROTEIN TYROSINE KINASE INHIBITORS
WO2004065378A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE602004017474D1 (en) * 2003-07-11 2008-12-11 Warner Lambert Co ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
WO2005047284A1 (en) 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
EP1786817A1 (en) * 2004-08-26 2007-05-23 Boehringer Ingelheim International GmbH Pteridinones used as plk (polo like kinases) inhibitors
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
US20090137550A1 (en) 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
AR053346A1 (en) 2005-03-25 2007-05-02 Glaxo Group Ltd COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38
PE20100741A1 (en) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPOUNDS DERIVED FROM 3,4-DIHYDROPYRIMIDE [4,5-d] PYRIMIDIN-2 (1H) -ONE AS KINASE INHIBITORS p38
EA200702073A1 (en) 2005-03-25 2008-12-30 Глэксо Груп Лимитед Method of producing pyrido [2,3-d] pyrimidine-7-bp and 3,4-dihidropyrimido [4,5-d] pyrmidin-2 (1h) -onovy derivatives
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (en) 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
EA201200669A1 (en) 2005-10-07 2012-11-30 Экселиксис, Инк. PYRIDOPYRIMIDINONE INHIBITORS PI3Kα
ES2432046T3 (en) * 2005-10-07 2013-11-29 Exelixis, Inc. PI3Kalfa inhibitor pyridopyrimidinones
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2008032162A1 (en) 2006-09-15 2008-03-20 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
CA2665384A1 (en) * 2006-10-16 2008-04-24 Gpc Biotech Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
RS52862B (en) * 2007-04-03 2013-12-31 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
WO2008153207A1 (en) * 2007-06-15 2008-12-18 Banyu Pharmaceutical Co., Ltd Bicycloaniline derivative
EP3098223A1 (en) 2007-08-03 2016-11-30 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
EP2225226B1 (en) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
JP2012504628A (en) 2008-09-30 2012-02-23 エグゼリクシス， インコーポレイテッド Pyridopyrimidinone inhibitors of PI3Kα and mTOR
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
AU2010303218A1 (en) * 2009-10-09 2012-05-10 Afraxis Holdings, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8H)-ones for the treatment of CNS disorders
JP5797664B2 (en) * 2009-12-18 2015-10-21 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ Substituted pyrido [2,3-d] pyrimidin-7 (8H) -ones and their therapeutic use
UY33221A (en) 2010-02-09 2011-09-30 Univ California METHODS TO TREAT CANCER USING PI3K AND mTOR INHIBITORS IN COMBINATION WITH AUTOPHAGIA INHIBITORS
EP3235818A3 (en) 2010-04-01 2018-03-14 Critical Outcome Technologies, Inc. Compounds for the treatment of hiv
BR112013002375B1 (en) 2010-08-05 2020-05-12 Temple University - Of The Commonwealth System Of Higher Education COMPOUND, SAME PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION, AND, USES OF A COMPOUND
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
PT2646448T (en) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Macrocyclic kinase inhibitors
EP2688887B1 (en) 2011-03-23 2015-05-13 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
PL2710005T3 (en) * 2011-05-17 2017-07-31 Principia Biopharma Inc. Tyrosine kinase inhibitors
MX2014010176A (en) 2012-02-23 2014-11-10 Abbvie Inc Pyridopyrimidinone inhibitors of kinases.
ES2694787T3 (en) * 2013-02-21 2018-12-27 Pfizer Inc. Solid forms of a selective CDK4 / 6 inhibitor
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
AU2015296322B2 (en) * 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (en) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
PT3497103T (en) 2016-08-15 2021-06-17 Pfizer Pyridopyrimdinone cdk2/4/6 inhibitors
EP3589634A4 (en) * 2017-03-03 2020-08-12 Auckland Uniservices Limited FGFR KINASE INHIBITORS AND PHARMACEUTICAL USES
AU2019220746A1 (en) 2018-02-15 2020-08-27 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2020114519A1 (en) * 2018-12-07 2020-06-11 杭州英创医药科技有限公司 Heterocyclic compound as cdk-hdac dual pathway inhibitor
CN112759589B (en) * 2019-11-01 2022-04-08 暨南大学 Pyrimidopyridinones and their use
CN114901659A (en) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 Fused pyrimidinone compounds as JAK inhibitors
WO2022188755A1 (en) * 2021-03-08 2022-09-15 暨南大学 Pyridopyrimidine-based compound and application thereof
KR20240021239A (en) * 2021-06-09 2024-02-16 티와이케이 메디슨즈, 인코포레이티드 Compounds used as CDK kinase inhibitors and their uses
EP4588917A1 (en) * 2022-09-16 2025-07-23 East China Normal University Pyridonopyrimidine derivative as rsk inhibitor and use thereof
CN120202198A (en) * 2022-11-10 2025-06-24 北京普祺医药科技股份有限公司 Sulfide compound with soft drug properties, pharmaceutical composition and use thereof
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
DE69839338T2 (en) * 1997-02-05 2008-07-10 Warner-Lambert Company Llc PYRIDO (2,3-D) PYRIMIDINE AND 4-AMINO-PYRIMIDINE AS INHIBITORS OF CELLULAR PROLIFERATION
WO1999061444A2 (en) * 1998-05-26 1999-12-02 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

Also Published As

Publication number Publication date
MXPA02008535A (en) 2002-12-13
HRP20020798A2 (en) 2004-02-29
CR6736A (en) 2004-03-10
WO2001070741A1 (en) 2001-09-27
CN1422268A (en) 2003-06-04
IL151480A0 (en) 2003-04-10
NZ520962A (en) 2003-09-26
NO20024235L (en) 2002-11-05
OA12227A (en) 2004-03-18
GT200100037A (en) 2002-03-04
HN2001000040A (en) 2001-09-06
EA200200802A1 (en) 2003-02-27
AR034119A1 (en) 2004-02-04
CZ20022929A3 (en) 2003-02-12
PE20011177A1 (en) 2001-11-23
EP1268476A1 (en) 2003-01-02
SV2001000338A (en) 2001-11-30
YU66502A (en) 2005-09-19
MA26881A1 (en) 2004-12-20
CA2401368A1 (en) 2001-09-27
CO5280200A1 (en) 2003-05-30
PL358271A1 (en) 2004-08-09
BG107161A (en) 2003-06-30
AU2001233028A1 (en) 2001-10-03
NO20024235D0 (en) 2002-09-05
IS6524A (en) 2002-08-23
KR20020075805A (en) 2002-10-05
PA8513201A1 (en) 2003-06-30
EE200200506A (en) 2004-02-16
HUP0300136A2 (en) 2003-05-28
BR0109056A (en) 2003-06-03
JP2003528101A (en) 2003-09-24
AP2002002643A0 (en) 2002-12-31
TNSN01036A1 (en) 2005-11-10
ZA200207110B (en) 2003-12-04
SK12472002A3 (en) 2003-04-01

Similar Documents

Publication Publication Date Title
DZ3308A1 (en) 5-alkylpyrido [2,3-d] pyrimidines tyrosine kinase inhibitors
EG24381A (en) Tyrosine kinase inhibitors
EP1161433A4 (en) Tyrosine kinase inhibitors
AU2000240570A1 (en) Pyrrolopyrimidines as tyrosine kinase inhibitors
EE200200405A (en) Pyrido [2,3-d] pyrimidine-2,7-diamines as kinase inhibitors
IL159832A0 (en) 4-amino-6-phenyl-pyrrolo[2,3-d] pyrimidine derivatives
MXPA03008690A (en) Novel tyrosine kinase inhibitors.
ZA200206386B (en) Kinase inhibitors.
AU2002361577A1 (en) Tyrosine kinase inhibitors
EP1259236A4 (en) Tyrosine kinase inhibitors
AU2002348394A1 (en) Tyrosine kinase inhibitors
AU2002348020A1 (en) Tyrosine kinase inhibitors
AU2002348393A1 (en) Tyrosine kinase inhibitors
PL358551A1 (en) 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU2002327534A1 (en) Tyrosine kinase inhibitors
MXPA03004498A (en) Use of pyrazolo[4,3-d]pyrimidines.
MXPA03004907A (en) Use of pyrazolo[4,3-d]pyrimidines.
AU8578501A (en) 2-aminoalkyl-thieno(2,3-d)pyrimidines
GB0013807D0 (en) Tyrosine kinase modulators
HK1044939A (en) Tyrosine kinase inhibitors
AU2002326865A1 (en) Tyrosine kinase inhibitors
AU2002355733A1 (en) Tyrosine kinase inhibitors
AU2002322568A1 (en) Tyrosine kinase inhibitors
AU2002337972A1 (en) Tyrosine kinase inhibitors